IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
IDEAYA Biosciences (Nasdaq: IDYA) has announced its upcoming 10-Year Anniversary R&D Day, scheduled for September 8, 2025, from 8:00 AM to 10:00 AM ET in New York City. The event will be accessible both in-person and virtually.
The R&D Day will feature presentations of multiple clinical data updates across the company's pipeline, along with discussions about future growth drivers and upcoming milestones. The event will include presentations from IDEAYA's senior leadership team and key opinion leaders in precision medicine oncology.
CEO Yujiro S. Hata will outline the company's strategic vision, priority scientific focus areas, and emerging clinical pipeline as IDEAYA positions itself as a global leader in precision medicine oncology.
IDEAYA Biosciences (Nasdaq: IDYA) ha annunciato il suo prossimo R&D Day per il 10掳 anniversario, previsto per il 8 settembre 2025, dalle 8:00 alle 10:00 ET a New York City. L'evento sar脿 disponibile sia in presenza che virtualmente.
Durante il R&D Day saranno presentati aggiornamenti su diversi dati clinici relativi alla pipeline dell'azienda, insieme a discussioni sui futuri driver di crescita e le prossime tappe importanti. Interverranno il team di leadership senior di IDEAYA e importanti esperti di medicina di precisione oncologica.
Il CEO Yujiro S. Hata illustrer脿 la visione strategica dell'azienda, le aree scientifiche prioritarie e la pipeline clinica emergente, mentre IDEAYA si posiziona come leader globale nella medicina di precisione oncologica.
IDEAYA Biosciences (Nasdaq: IDYA) ha anunciado su pr贸ximo D铆a de I+D por el 10潞 aniversario, programado para el 8 de septiembre de 2025, de 8:00 a 10:00 AM ET en la ciudad de Nueva York. El evento ser谩 accesible tanto en persona como de forma virtual.
El D铆a de I+D incluir谩 presentaciones con m煤ltiples actualizaciones de datos cl铆nicos a lo largo del pipeline de la compa帽铆a, adem谩s de discusiones sobre futuros motores de crecimiento y pr贸ximos hitos. El evento contar谩 con presentaciones del equipo de liderazgo senior de IDEAYA y l铆deres de opini贸n clave en oncolog铆a de medicina de precisi贸n.
El CEO Yujiro S. Hata expondr谩 la visi贸n estrat茅gica de la compa帽铆a, las 谩reas cient铆ficas prioritarias y la pipeline cl铆nica emergente, mientras IDEAYA se posiciona como l铆der global en oncolog铆a de medicina de precisi贸n.
IDEAYA 氚旍澊鞓れ偓鞚挫柛鞁滌姢(Nasdaq: IDYA)電� 2025雲� 9鞗� 8鞚� 鞓れ爠 8鞁滊秬韯� 10鞁�(霃欕秬鞁滉皠)旯岇 雺挫殨鞁滌棎靹� 鞐措Μ電� 10欤茧厔 鞐瓣惮臧滊皽(R&D) 雿办澊 頄夓偓毳� 氚滍憸頄堨姷雼堧嫟. 頃措嫻 頄夓偓電� 順勳灔 彀胳劃瓿� 鞓澕鞚� 氇憪鞐愳劀 彀胳棳頃� 靾� 鞛堨姷雼堧嫟.
R&D 雿办澊鞐愳劀電� 須岇偓鞚� 韺岇澊頂勲澕鞚� 鞝勲皹鞐� 瓯胳箿 雼れ枒頃� 鞛勳儊 雿办澊韯� 鞐呺嵃鞚错姼臧� 氚滍憸霅橂┌, 頄ロ泟 靹膘灔 霃欕牓瓿� 雼り皜鞓る姅 欤检殧 鞚挫爼響滌棎 雽�頃� 雲检潣臧� 歆勴枆霅╇媹雼�. IDEAYA鞚� 瓿犾渼 瓴届榿歆勱臣 鞝曤皜 鞚橅暀 膦呾枒頃� 攵勳暭鞚� 欤检殧 鞚橁铂 毽崝霌れ澊 氚滍憸鞐� 彀胳棳頃╇媹雼�.
CEO 鞙犾搿� S. 頃橅儉電� 須岇偓鞚� 鞝勲灥鞝� 牍勳爠, 鞖办劆 瓿柬暀 攵勳暭 氚� 鞁犿潵 鞛勳儊 韺岇澊頂勲澕鞚胳潉 靹る獏頃橂┌ IDEAYA臧� 鞝曤皜 鞚橅暀 膦呾枒頃� 攵勳暭鞚� 旮�搿滊矊 毽崝搿� 鞛愲Μ毵り箑頃橂姅 氇姷鞚� 鞝滌嫓頃� 鞓堨爼鞛呺媹雼�.
IDEAYA Biosciences (Nasdaq : IDYA) a annonc茅 sa prochaine Journ茅e R&D pour son 10e anniversaire, pr茅vue le 8 septembre 2025, de 8h00 脿 10h00 ET 脿 New York. L'茅v茅nement sera accessible 脿 la fois en pr茅sentiel et en virtuel.
La Journ茅e R&D comprendra des pr茅sentations de plusieurs mises 脿 jour de donn茅es cliniques concernant le pipeline de l'entreprise, ainsi que des discussions sur les futurs moteurs de croissance et les 茅tapes 脿 venir. Des pr茅sentations seront faites par l'茅quipe de direction senior d'IDEAYA ainsi que par des leaders d'opinion cl茅s en oncologie de m茅decine de pr茅cision.
Le PDG Yujiro S. Hata exposera la vision strat茅gique de l'entreprise, les domaines scientifiques prioritaires et le pipeline clinique 茅mergent, alors qu'IDEAYA se positionne comme un leader mondial en oncologie de m茅decine de pr茅cision.
IDEAYA Biosciences (Nasdaq: IDYA) hat seinen bevorstehenden 10-j盲hrigen Jubil盲ums-R&D-Tag angek眉ndigt, der f眉r den 8. September 2025 von 8:00 bis 10:00 Uhr ET in New York City geplant ist. Die Veranstaltung wird sowohl vor Ort als auch virtuell zug盲nglich sein.
Der R&D-Tag umfasst Pr盲sentationen mit mehreren klinischen Datenupdates aus der Pipeline des Unternehmens sowie Diskussionen 眉ber zuk眉nftige Wachstumstreiber und bevorstehende Meilensteine. Pr盲sentationen werden vom Senior-Management-Team von IDEAYA und wichtigen Meinungsf眉hrern im Bereich der Pr盲zisionsmedizin-Onkologie gehalten.
CEO Yujiro S. Hata wird die strategische Vision des Unternehmens, die priorit盲ren wissenschaftlichen Fokusbereiche und die aufstrebende klinische Pipeline vorstellen, w盲hrend IDEAYA sich als globaler Marktf眉hrer in der Pr盲zisionsmedizin-Onkologie positioniert.
- None.
- None.
"This year marks IDEAYA's ten-year anniversary since our founding, and we look forward to providing multiple clinical data updates across our potential first-in-class pipeline, and highlight our strategic vision, priority areas of scientific focus, and emerging clinical pipeline that will drive the next phase of our growth as a global leader in precision medicine oncology," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
Speakers will include members of IDEAYA's senior leadership team and key opinion leader(s).聽
Registration for this event can be accessed here or at the investors section of the IDEAYA website at .
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at a certain investor relation event. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]
View original content to download multimedia:
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) R&D Day 2025 and how can investors attend?
What will be presented at IDEAYA Biosciences' (IDYA) 2025 R&D Day?
Who will be speaking at IDEAYA's (IDYA) 2025 R&D Day?
How can I access IDEAYA Biosciences' (IDYA) R&D Day presentation?
